1
|
Belvís R, Santos-Lasaosa S, Irimia P, Blanco RL, Torres-Ferrús M, Morollón N, López-Bravo A, García-Azorín D, Mínguez-Olaondo A, Guerrero Á, Porta J, Giné-Ciprés E, Sierra Á, Latorre G, González-Oria C, Pascual J, Ezpeleta D. Telemedicine in the management of patients with headache: current situation and recommendations of the Spanish Society of Neurology's Headache Study Group. Neurologia 2023; 38:635-646. [PMID: 37858888 DOI: 10.1016/j.nrleng.2023.10.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2021] [Accepted: 01/31/2021] [Indexed: 10/21/2023] Open
Abstract
INTRODUCTION The COVID-19 pandemic has caused an unexpected boost to telemedicine. We analyse the impact of the pandemic on telemedicine applied in Spanish headache consultations, review the literature, and issue recommendations for the implementation of telemedicine in consultations. METHOD The study comprised 3 phases: 1) review of the MEDLINE database since 1958 (first reported experience with telemedicine); 2) Google Forms survey sent to all members of the Spanish Society of Neurology's Headache Study Group (GECSEN); and 3) online consensus of GECSEN experts to issue recommendations for the implementation of telemedicine in Spain. RESULTS COVID-19 has increased waiting times for face-to-face consultations, increasing the use of all telemedicine modalities: landline telephone (from 75% before April 2020 to 97% after), mobile telephone (from 9% to 27%), e-mail (from 30% to 36%), and video consultation (from 3% to 21%). Neurologists are aware of the need to expand the availability of video consultations, which are clearly growing, and other e-health and m-health tools. CONCLUSIONS The GECSEN recommends and encourages all neurologists who assist patients with headaches to implement telemedicine resources, with the optimal objective of offering video consultation to patients under 60-65 years of age and telephone calls to older patients, although each case must be considered on an individual basis. Prior approval and advice must be sought from legal and IT services and the centre's management. Most patients with stable headache and/or neuralgia are eligible for telemedicine follow-up, after a first consultation that must always be held in person.
Collapse
Affiliation(s)
- R Belvís
- Servicio de Neurología, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
| | - S Santos-Lasaosa
- Servicio de Neurología, Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain; Instituto de Investigación Sanitaria Aragón, Zaragoza, Spain
| | - P Irimia
- Servicio de Neurología, Clínica Universidad de Navarra, Pamplona, Spain
| | - R L Blanco
- Servicio Integrado de Neurología, Hospital Universitario Rey Juan Carlos, Móstoles, Spain; Hospital General de Villalba, Hospital Universitario Infanta Elena, Valdemoro, Spain
| | - M Torres-Ferrús
- Servicio de Neurología, Hospital Universitario Vall d'Hebron, Barcelona, Spain
| | - N Morollón
- Departamento de Neurología, Hospital Reina Sofía, Tudela, Navarra, Spain
| | - A López-Bravo
- Instituto de Investigación Sanitaria Aragón, Zaragoza, Spain; Departamento de Neurología, Hospital Reina Sofía, Tudela, Navarra, Spain
| | - D García-Azorín
- Servicio de Neurología, Hospital Clínico Universitario de Valladolid, Valladolid, Spain
| | | | - Á Guerrero
- Servicio de Neurología, Hospital Clínico Universitario de Valladolid, Valladolid, Spain
| | - J Porta
- Servicio de Neurología, Hospital Clínico Universitario San Carlos, Madrid, Spain
| | - E Giné-Ciprés
- Servicio de Neurología, Hospital Universitario Vall d'Hebron, Barcelona, Spain
| | - Á Sierra
- Servicio de Neurología, Hospital Clínico Universitario de Valladolid, Valladolid, Spain
| | - G Latorre
- Departamento de Neurología, Hospital Universitario de Fuenlabrada, Madrid, Spain
| | - C González-Oria
- Servicio de Neurología, Hospital Universitario Virgen del Rocío, Sevilla, Spain
| | - J Pascual
- Servicio de Neurología, Hospital Universitario Marqués de Valdecilla e IDIVAL y Universidad de Cantabria, Santander, Spain
| | - D Ezpeleta
- Servicio de Neurología, Hospital Universitario Quirónsalud Madrid, Pozuelo de Alarcón, Madrid, Spain
| |
Collapse
|
2
|
Soriano M, Del Castillo L, Subirá J, Herrera A, Guerrero Á, Gavilá J, Santaballa A, Díaz-García C. P-481 Characterization of the gene expression profile of breast cancer tumours in patients undergoing ovarian stimulation for fertility preservation purposes. Hum Reprod 2022. [DOI: 10.1093/humrep/deac105.015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Study question
Could controlled ovarian stimulation (COS) protocols with letrozole supplementation induce changes in the molecular footprints of estrogen receptor-positive (ER+) breast cancer (BC) women?
Summary answer
Ovarian stimulation with letrozole and gonadotropins does not change the gene expression profile of estrogen receptor-positive (ER+) breast malignant tumours as compared to non-stimulated patients.
What is known already
Fertility preservation (FP) strategies in ER+ BC patients involve modifications of the classical COS protocols to minimise the impact of estrogen levels during ovarian stimulation. The most common approaches are using the aromatase inhibitor letrozole to block the conversion of testosterone into estradiol in the granulosa cells or the use of tamoxifen to block the ER in the breast tissue. Although retrospective studies suggest that these strategies will have no impact on patient’s survival and disease progression, little is known regarding the effect of the ovarian stimulation on the genomic fingerprints of the exposed cancerous tissue.
Study design, size, duration
Retrospective, non-randomized, comparative study. Gene expression profiles were compared in biopsies at diagnosis and during excision surgery in two groups of ER+ BC patients: Patients undergoing COS for FP before surgery (COS group, n = 10) and patients not undergoing any type of COS (Control group, n = 11). The former received letrozole (5mg/day) supplements during COS. The latter included 7 patients not doing FP and 4 undergoing ovarian cortex cryopreservation. Patients were recruited between 2009 and 2021.
Participants/materials, setting, methods
Single 5-µm sections of formalin-fixed, paraffin-embedded (FFPE) needle core biopsy (NCB) and breast surgery (BS) tumour samples were obtained prior to starting gonadotoxic therapies. Differential gene expression and gene set analysis (GSA) was performed in tumour samples before (NCB-sample) and after COS (BS-sample). Simultaneous, quantitative detection of 2549 genes associated with tumour biology was performed with the HTG EdgeSeq Oncology Biomarker Panel. Tumour cell proliferation was also assessed by Ki67 staining.
Main results and the role of chance
Patients were younger in the COS group (COS: 30.2±3.4 vs Control: 34.5±2.3; p = 0.004). None of the patients experienced any relapse during the observation period. The length of COS was 11.5±3.5 days and 10.6±6.8 MII oocytes were vitrified. The exploratory analysis using principal component analysis revealed no relationships between the two BC biopsy samples and gene expression levels in the experimental groups. The differential expression analysis just revealed 6 genes significantly over-expressed after ovarian stimulation (DUSP1, FOS, EGFR1, NR4A1, JUN and CYR61). From these, DUSP1, FOS, and NR4A1 were also significantly upregulated in the unstimulated group. The GSA showed the cytochrome P450 pathway was significantly enriched after COS. No pathways related to cell proliferation were differentially expressed between groups. However, in unstimulated patients, 6 KEGG pathways were upregulated, with the cytokine-cytokine receptor interaction and the Jak-STAT signalling pathway being the most enriched. Ki67 immunostaining showed no differences in cell proliferation after COS (22.8±7.2 vs 24.0±6.9, p = 0.723). The rate of cell proliferation also remained constant in unstimulated patients (22.9±8.4 vs 25.1±8.1, p = 0.560).
Limitations, reasons for caution
The main limitations of the present study are the retrospective design and the associated risk of bias, although the population is very homogeneous when it comes to clinical characteristics; and the fact that molecular footprints are only interim markers of survival/response to the treatment.
Wider implications of the findings
The present study provides molecular evidence supporting the safety of COS using letrozole for oocyte vitrification in young BC patients undergoing ovarian stimulation. This information is crucial to support patient guidance during discussions about fertility preservation.
Trial registration number
Not applicable
Collapse
Affiliation(s)
- M.J Soriano
- Fundación IVI - Instituto de Investigación Sanitaria La Fe IISLAFE, Grupo de investigación en Medicina Reproductiva- Fundación IVI , Valencia, Spain
| | - L.M Del Castillo
- Fundación IVI - Instituto de Investigación Sanitaria La Fe IISLAFE, Grupo de investigación en Medicina Reproductiva- Fundación IVI , Valencia, Spain
- University of Valencia, Dept. Pediatrics- Obstetrics and Gynecology , Valencia, Spain
| | - J Subirá
- IVIRMA Global, IVI Valencia , Valencia, Spain
| | - A Herrera
- Hospital Universitario y Politécnico La Fe, Anatomical Pathology , Valencia, Spain
| | - Á Guerrero
- Fundación Instituto Valenciano de Oncología, Medical Oncology Department , Valencia, Spain
| | - J Gavilá
- Fundación Instituto Valenciano de Oncología, Medical Oncology Department , Valencia, Spain
| | - A Santaballa
- Hospital Universitario y Politécnico La Fe, Medical Oncology , Valencia, Spain
| | - C Díaz-García
- Fundación IVI - Instituto de Investigación Sanitaria La Fe IISLAFE, Grupo de investigación en Medicina Reproductiva- Fundación IVI , Valencia, Spain
- University College London, EGA Institute for Women’s Health , London, United Kingdom
- IVI-RMA Global, IVI London , London, United Kingdom
| |
Collapse
|
3
|
Belvís R, Santos-Lasaosa S, Irimia P, López Blanco R, Torres-Ferrús M, Morollón N, López-Bravo A, García-Azorín D, Mínguez-Olaondo A, Guerrero Á, Porta J, Giné-Ciprés E, Sierra Á, Latorre G, González-Oria C, Pascual J, Ezpeleta D. Telemedicine in the management of patients with headache: current situation and recommendations of the Spanish Society of Neurology's Headache Study Group. Neurologia 2021; 38:S0213-4853(21)00054-2. [PMID: 33867184 DOI: 10.1016/j.nrl.2021.01.018] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2021] [Accepted: 01/31/2021] [Indexed: 11/25/2022] Open
Abstract
INTRODUCTION The COVID-19 pandemic has caused an unexpected boost to telemedicine. We analyse the impact of the pandemic on telemedicine applied in Spanish headache consultations, review the literature, and issue recommendations for the implementation of telemedicine in consultations. METHOD The study comprised 3 phases: 1) review of the MEDLINE database since 1958 (first reported experience with telemedicine); 2) Google Forms survey sent to all members of the Spanish Society of Neurology's Headache Study Group (GECSEN); and 3) online consensus of GECSEN experts to issue recommendations for the implementation of telemedicine in Spain. RESULTS COVID-19 has increased waiting times for face-to-face consultations, increasing the use of all telemedicine modalities: landline telephone (from 75% before April 2020 to 97% after), mobile telephone (from 9% to 27%), e-mail (from 30% to 36%), and video consultation (from 3% to 21%). Neurologists are aware of the need to expand the availability of video consultations, which are clearly growing, and other e-health and m-health tools. CONCLUSIONS The GECSEN recommends and encourages all neurologists who assist patients with headaches to implement telemedicine resources, with the optimal objective of offering video consultation to patients under 60-65 years of age and telephone calls to older patients, although each case must be considered on an individual basis. Prior approval and advice must be sought from legal and IT services and the centre's management. Most patients with stable headache and/or neuralgia are eligible for telemedicine follow-up, after a first consultation that must always be held in person.
Collapse
Affiliation(s)
- R Belvís
- Servicio de Neurología, Hospital de la Santa Creu i Sant Pau, Barcelona, España.
| | - S Santos-Lasaosa
- Servicio de Neurología, Hospital Clínico Universitario Lozano Blesa, Zaragoza, España; Instituto de Investigación Sanitaria Aragón, Zaragoza, España
| | - P Irimia
- Servicio de Neurología, Clínica Universidad de Navarra, Pamplona, España
| | - R López Blanco
- Servicio Integrado de Neurología, Hospital Universitario Rey Juan Carlos, Móstoles, España; Hospital General de Villalba, Hospital Universitario Infanta Elena, Valdemoro, España
| | - M Torres-Ferrús
- Servicio de Neurología, Hospital Universitario Vall d'Hebron, Barcelona, España
| | - N Morollón
- Servicio de Neurología, Hospital de la Santa Creu i Sant Pau, Barcelona, España
| | - A López-Bravo
- Instituto de Investigación Sanitaria Aragón, Zaragoza, España; Departamento de Neurología, Hospital Reina Sofía, Tudela, Navarra, España
| | - D García-Azorín
- Servicio de Neurología, Hospital Clínico Universitario de Valladolid, Valladolid, España
| | | | - Á Guerrero
- Servicio de Neurología, Hospital Clínico Universitario de Valladolid, Valladolid, España
| | - J Porta
- Servicio de Neurología, Hospital Clínico Universitario San Carlos, Madrid, España
| | - E Giné-Ciprés
- Servicio de Neurología, Hospital Universitario Vall d'Hebron, Barcelona, España
| | - Á Sierra
- Servicio de Neurología, Hospital Clínico Universitario de Valladolid, Valladolid, España
| | - G Latorre
- Departamento de Neurología, Hospital Universitario de Fuenlabrada, Madrid, España
| | - C González-Oria
- Servicio de Neurología, Hospital Universitario Virgen del Rocío, Sevilla, España
| | - J Pascual
- Servicio de Neurología, Hospital Universitario Marqués de Valdecilla e IDIVAL y Universidad de Cantabria, Santander, España
| | - D Ezpeleta
- Servicio de Neurología, Hospital Universitario Quirónsalud Madrid, Pozuelo de Alarcón, Madrid, España
| |
Collapse
|
4
|
Prat A, de la Haba-Rodriguez J, Guerrero Á, García-Sáenz JA, Morales S, Antón A, Muñoz M, Ramos M, Martínez-Jáñez N, Margelí M, Servitja S, Rojo F, Galván P, González S, Cruz J, Sánchez-Rovira P, Perelló A, Rodríguez-Martin C, Casas M, Carrasco E, Caballero R, Martín M. Abstract P3-07-42: Predicting outcome and benefit to first-line bevacizumab in advanced/metastatic hormone receptor (HR)+/HER2-negative breast cancer (BC) treated with endocrine therapy: A correlative science study from the LEA phase III clinical trial (GEICAM/2006-11_GBG 051). Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p3-07-42] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: The role of bevacizumab in combination with chemotherapy in metastatic BC is controversial, and no biomarker exists as of today that predicts benefit to this agent. In the LEA clinical trial, a numerical, statistically non-significant benefit from the addition of bevacizumab to endocrine therapy (ET) was observed in the first-line metastatic setting (18.4 vs. 13.8 months of Progression-Free Survival (PFS), p=0.14). Here, we explored various gene expression-based predictors of outcome and benefit to bevacizumab.
Methods and materials: LEA trial randomized 380 patients with HR+/HER2- advanced disease to bevacizumab in combination with ET (ET+B) vs. ET alone. Primary endpoint was PFS. Expression of BC selected genes was evaluated in formalin-fixed paraffin-embedded (FFPE) primary tumors using the nCounter platform from patients randomized in Spain that consent for biomarker analyses. The following variables were evaluated: 1) research-based PAM50 intrinsic subtypes (categorical variable; Luminal A, Luminal B, HER2-enriched, Basal-like and Normal-like); 2) research-based PAM50 signatures (continuous variable; scores showing the distant of the gene expression values of an individual sample compared to the centroid gene values for each PAM50 intrinsic subtype); 3) risk of recurrence (ROR) groups (low, medium and high); 4) the 13-gene hypoxia/VEGF signature (continuous); and 5) Ki67 by immunohistochemistry (continuous). Uni- and multivariable Cox models for PFS were used to test the prognostic significance of each variable. To determine whether each variable is predictive of bevacizumab benefit, we tested the interaction term of each variable by treatment arm in a Cox model.
Results: Tumor samples from 103 patients were analyzed: 55 (53%) in ET+B arm and 49 (47%) in ET arm. Subtype distribution was as follows: 57 (55.3%) Luminal A, 32 (31.1%) Luminal B, 5 (4.9%) HER2-enriched, 1 (1.0%) Basal-like, and 8 (7.8%) normal-like. In a univariate analysis, Luminal B tumors had a poorer outcome using Luminal A as reference (13.8 vs. 21.3 months, respectively; (hazard ratio, HR=1.80, 95% CI 1.10-2.95, p=0.019). Concordant with this finding, Luminal A signature was associated with a better outcome. Similarly, ROR-P high group showed a poorer outcome than ROR-P low group (8.5 vs. 19.4 months; HR=2.88, 95% CI 1.30-6.35, p=0.009). Neither VEGF-13 signature nor Ki67 were found to be associated with PFS. Similar findings were obtained after adjustment for treatment, age, previous ET, ECOG, visceral disease and number of metastatic sites. In terms of treatment benefit, the HER2-enriched signature was the only variable found predictive of bevacizumab PFS benefit in univariate (p=0.010) and multivariate (p=0.015) analyses.
Conclusions: In advanced HR+/HER2- disease, intrinsic subtype (i.e. Luminal A vs. B) independently predicts PFS following first-line ET. In addition, HR+/HER2-negative tumors with high expression of the HER2-enriched signature, a biomarker of estrogen-independence, benefit the most from bevacizumab. Further validation of these prognostic and predictive biomarkers is warranted.
Citation Format: Prat A, de la Haba-Rodriguez J, Guerrero Á, García-Sáenz JA, Morales S, Antón A, Muñoz M, Ramos M, Martínez-Jáñez N, Margelí M, Servitja S, Rojo F, Galván P, González S, Cruz J, Sánchez-Rovira P, Perelló A, Rodríguez-Martin C, Casas M, Carrasco E, Caballero R, Martín M. Predicting outcome and benefit to first-line bevacizumab in advanced/metastatic hormone receptor (HR)+/HER2-negative breast cancer (BC) treated with endocrine therapy: A correlative science study from the LEA phase III clinical trial (GEICAM/2006-11_GBG 051). [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P3-07-42.
Collapse
Affiliation(s)
- A Prat
- Translational Genomics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Hospital Clínic de Barcelona, Barcelona, Spain; Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC)– H. Universitario Reina Sofía, Universidad de Córdoba, Córdoba, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Clínico San Carlos, Madrid, Spain; Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain; Hospital Universitario Miguel Servet, Zaragoza, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Hospital Universitario Ramón y Cajal, Madrid, Spain; Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain; Hospital del Mar, Barcelona, Spain; Fundación Jiménez Díaz, Madrid, Spain; Hospital Universitari Mutua de Terrassa, Terrassa, Barcelona, Spain; Hospital Universitario de Canarias, La Laguna, Tenerife, Spain; Complejo Hospitalario de Jaén, Jaén, Spain; Hospital Universitari Son Espases, Palma de Mallorca, Spain; GEICAM, Spanish Breast Cancer Group, Madr
| | - J de la Haba-Rodriguez
- Translational Genomics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Hospital Clínic de Barcelona, Barcelona, Spain; Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC)– H. Universitario Reina Sofía, Universidad de Córdoba, Córdoba, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Clínico San Carlos, Madrid, Spain; Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain; Hospital Universitario Miguel Servet, Zaragoza, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Hospital Universitario Ramón y Cajal, Madrid, Spain; Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain; Hospital del Mar, Barcelona, Spain; Fundación Jiménez Díaz, Madrid, Spain; Hospital Universitari Mutua de Terrassa, Terrassa, Barcelona, Spain; Hospital Universitario de Canarias, La Laguna, Tenerife, Spain; Complejo Hospitalario de Jaén, Jaén, Spain; Hospital Universitari Son Espases, Palma de Mallorca, Spain; GEICAM, Spanish Breast Cancer Group, Madr
| | - Á Guerrero
- Translational Genomics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Hospital Clínic de Barcelona, Barcelona, Spain; Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC)– H. Universitario Reina Sofía, Universidad de Córdoba, Córdoba, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Clínico San Carlos, Madrid, Spain; Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain; Hospital Universitario Miguel Servet, Zaragoza, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Hospital Universitario Ramón y Cajal, Madrid, Spain; Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain; Hospital del Mar, Barcelona, Spain; Fundación Jiménez Díaz, Madrid, Spain; Hospital Universitari Mutua de Terrassa, Terrassa, Barcelona, Spain; Hospital Universitario de Canarias, La Laguna, Tenerife, Spain; Complejo Hospitalario de Jaén, Jaén, Spain; Hospital Universitari Son Espases, Palma de Mallorca, Spain; GEICAM, Spanish Breast Cancer Group, Madr
| | - JA García-Sáenz
- Translational Genomics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Hospital Clínic de Barcelona, Barcelona, Spain; Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC)– H. Universitario Reina Sofía, Universidad de Córdoba, Córdoba, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Clínico San Carlos, Madrid, Spain; Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain; Hospital Universitario Miguel Servet, Zaragoza, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Hospital Universitario Ramón y Cajal, Madrid, Spain; Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain; Hospital del Mar, Barcelona, Spain; Fundación Jiménez Díaz, Madrid, Spain; Hospital Universitari Mutua de Terrassa, Terrassa, Barcelona, Spain; Hospital Universitario de Canarias, La Laguna, Tenerife, Spain; Complejo Hospitalario de Jaén, Jaén, Spain; Hospital Universitari Son Espases, Palma de Mallorca, Spain; GEICAM, Spanish Breast Cancer Group, Madr
| | - S Morales
- Translational Genomics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Hospital Clínic de Barcelona, Barcelona, Spain; Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC)– H. Universitario Reina Sofía, Universidad de Córdoba, Córdoba, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Clínico San Carlos, Madrid, Spain; Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain; Hospital Universitario Miguel Servet, Zaragoza, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Hospital Universitario Ramón y Cajal, Madrid, Spain; Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain; Hospital del Mar, Barcelona, Spain; Fundación Jiménez Díaz, Madrid, Spain; Hospital Universitari Mutua de Terrassa, Terrassa, Barcelona, Spain; Hospital Universitario de Canarias, La Laguna, Tenerife, Spain; Complejo Hospitalario de Jaén, Jaén, Spain; Hospital Universitari Son Espases, Palma de Mallorca, Spain; GEICAM, Spanish Breast Cancer Group, Madr
| | - A Antón
- Translational Genomics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Hospital Clínic de Barcelona, Barcelona, Spain; Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC)– H. Universitario Reina Sofía, Universidad de Córdoba, Córdoba, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Clínico San Carlos, Madrid, Spain; Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain; Hospital Universitario Miguel Servet, Zaragoza, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Hospital Universitario Ramón y Cajal, Madrid, Spain; Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain; Hospital del Mar, Barcelona, Spain; Fundación Jiménez Díaz, Madrid, Spain; Hospital Universitari Mutua de Terrassa, Terrassa, Barcelona, Spain; Hospital Universitario de Canarias, La Laguna, Tenerife, Spain; Complejo Hospitalario de Jaén, Jaén, Spain; Hospital Universitari Son Espases, Palma de Mallorca, Spain; GEICAM, Spanish Breast Cancer Group, Madr
| | - M Muñoz
- Translational Genomics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Hospital Clínic de Barcelona, Barcelona, Spain; Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC)– H. Universitario Reina Sofía, Universidad de Córdoba, Córdoba, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Clínico San Carlos, Madrid, Spain; Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain; Hospital Universitario Miguel Servet, Zaragoza, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Hospital Universitario Ramón y Cajal, Madrid, Spain; Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain; Hospital del Mar, Barcelona, Spain; Fundación Jiménez Díaz, Madrid, Spain; Hospital Universitari Mutua de Terrassa, Terrassa, Barcelona, Spain; Hospital Universitario de Canarias, La Laguna, Tenerife, Spain; Complejo Hospitalario de Jaén, Jaén, Spain; Hospital Universitari Son Espases, Palma de Mallorca, Spain; GEICAM, Spanish Breast Cancer Group, Madr
| | - M Ramos
- Translational Genomics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Hospital Clínic de Barcelona, Barcelona, Spain; Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC)– H. Universitario Reina Sofía, Universidad de Córdoba, Córdoba, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Clínico San Carlos, Madrid, Spain; Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain; Hospital Universitario Miguel Servet, Zaragoza, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Hospital Universitario Ramón y Cajal, Madrid, Spain; Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain; Hospital del Mar, Barcelona, Spain; Fundación Jiménez Díaz, Madrid, Spain; Hospital Universitari Mutua de Terrassa, Terrassa, Barcelona, Spain; Hospital Universitario de Canarias, La Laguna, Tenerife, Spain; Complejo Hospitalario de Jaén, Jaén, Spain; Hospital Universitari Son Espases, Palma de Mallorca, Spain; GEICAM, Spanish Breast Cancer Group, Madr
| | - N Martínez-Jáñez
- Translational Genomics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Hospital Clínic de Barcelona, Barcelona, Spain; Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC)– H. Universitario Reina Sofía, Universidad de Córdoba, Córdoba, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Clínico San Carlos, Madrid, Spain; Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain; Hospital Universitario Miguel Servet, Zaragoza, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Hospital Universitario Ramón y Cajal, Madrid, Spain; Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain; Hospital del Mar, Barcelona, Spain; Fundación Jiménez Díaz, Madrid, Spain; Hospital Universitari Mutua de Terrassa, Terrassa, Barcelona, Spain; Hospital Universitario de Canarias, La Laguna, Tenerife, Spain; Complejo Hospitalario de Jaén, Jaén, Spain; Hospital Universitari Son Espases, Palma de Mallorca, Spain; GEICAM, Spanish Breast Cancer Group, Madr
| | - M Margelí
- Translational Genomics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Hospital Clínic de Barcelona, Barcelona, Spain; Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC)– H. Universitario Reina Sofía, Universidad de Córdoba, Córdoba, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Clínico San Carlos, Madrid, Spain; Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain; Hospital Universitario Miguel Servet, Zaragoza, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Hospital Universitario Ramón y Cajal, Madrid, Spain; Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain; Hospital del Mar, Barcelona, Spain; Fundación Jiménez Díaz, Madrid, Spain; Hospital Universitari Mutua de Terrassa, Terrassa, Barcelona, Spain; Hospital Universitario de Canarias, La Laguna, Tenerife, Spain; Complejo Hospitalario de Jaén, Jaén, Spain; Hospital Universitari Son Espases, Palma de Mallorca, Spain; GEICAM, Spanish Breast Cancer Group, Madr
| | - S Servitja
- Translational Genomics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Hospital Clínic de Barcelona, Barcelona, Spain; Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC)– H. Universitario Reina Sofía, Universidad de Córdoba, Córdoba, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Clínico San Carlos, Madrid, Spain; Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain; Hospital Universitario Miguel Servet, Zaragoza, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Hospital Universitario Ramón y Cajal, Madrid, Spain; Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain; Hospital del Mar, Barcelona, Spain; Fundación Jiménez Díaz, Madrid, Spain; Hospital Universitari Mutua de Terrassa, Terrassa, Barcelona, Spain; Hospital Universitario de Canarias, La Laguna, Tenerife, Spain; Complejo Hospitalario de Jaén, Jaén, Spain; Hospital Universitari Son Espases, Palma de Mallorca, Spain; GEICAM, Spanish Breast Cancer Group, Madr
| | - F Rojo
- Translational Genomics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Hospital Clínic de Barcelona, Barcelona, Spain; Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC)– H. Universitario Reina Sofía, Universidad de Córdoba, Córdoba, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Clínico San Carlos, Madrid, Spain; Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain; Hospital Universitario Miguel Servet, Zaragoza, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Hospital Universitario Ramón y Cajal, Madrid, Spain; Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain; Hospital del Mar, Barcelona, Spain; Fundación Jiménez Díaz, Madrid, Spain; Hospital Universitari Mutua de Terrassa, Terrassa, Barcelona, Spain; Hospital Universitario de Canarias, La Laguna, Tenerife, Spain; Complejo Hospitalario de Jaén, Jaén, Spain; Hospital Universitari Son Espases, Palma de Mallorca, Spain; GEICAM, Spanish Breast Cancer Group, Madr
| | - P Galván
- Translational Genomics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Hospital Clínic de Barcelona, Barcelona, Spain; Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC)– H. Universitario Reina Sofía, Universidad de Córdoba, Córdoba, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Clínico San Carlos, Madrid, Spain; Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain; Hospital Universitario Miguel Servet, Zaragoza, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Hospital Universitario Ramón y Cajal, Madrid, Spain; Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain; Hospital del Mar, Barcelona, Spain; Fundación Jiménez Díaz, Madrid, Spain; Hospital Universitari Mutua de Terrassa, Terrassa, Barcelona, Spain; Hospital Universitario de Canarias, La Laguna, Tenerife, Spain; Complejo Hospitalario de Jaén, Jaén, Spain; Hospital Universitari Son Espases, Palma de Mallorca, Spain; GEICAM, Spanish Breast Cancer Group, Madr
| | - S González
- Translational Genomics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Hospital Clínic de Barcelona, Barcelona, Spain; Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC)– H. Universitario Reina Sofía, Universidad de Córdoba, Córdoba, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Clínico San Carlos, Madrid, Spain; Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain; Hospital Universitario Miguel Servet, Zaragoza, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Hospital Universitario Ramón y Cajal, Madrid, Spain; Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain; Hospital del Mar, Barcelona, Spain; Fundación Jiménez Díaz, Madrid, Spain; Hospital Universitari Mutua de Terrassa, Terrassa, Barcelona, Spain; Hospital Universitario de Canarias, La Laguna, Tenerife, Spain; Complejo Hospitalario de Jaén, Jaén, Spain; Hospital Universitari Son Espases, Palma de Mallorca, Spain; GEICAM, Spanish Breast Cancer Group, Madr
| | - J Cruz
- Translational Genomics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Hospital Clínic de Barcelona, Barcelona, Spain; Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC)– H. Universitario Reina Sofía, Universidad de Córdoba, Córdoba, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Clínico San Carlos, Madrid, Spain; Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain; Hospital Universitario Miguel Servet, Zaragoza, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Hospital Universitario Ramón y Cajal, Madrid, Spain; Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain; Hospital del Mar, Barcelona, Spain; Fundación Jiménez Díaz, Madrid, Spain; Hospital Universitari Mutua de Terrassa, Terrassa, Barcelona, Spain; Hospital Universitario de Canarias, La Laguna, Tenerife, Spain; Complejo Hospitalario de Jaén, Jaén, Spain; Hospital Universitari Son Espases, Palma de Mallorca, Spain; GEICAM, Spanish Breast Cancer Group, Madr
| | - P Sánchez-Rovira
- Translational Genomics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Hospital Clínic de Barcelona, Barcelona, Spain; Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC)– H. Universitario Reina Sofía, Universidad de Córdoba, Córdoba, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Clínico San Carlos, Madrid, Spain; Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain; Hospital Universitario Miguel Servet, Zaragoza, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Hospital Universitario Ramón y Cajal, Madrid, Spain; Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain; Hospital del Mar, Barcelona, Spain; Fundación Jiménez Díaz, Madrid, Spain; Hospital Universitari Mutua de Terrassa, Terrassa, Barcelona, Spain; Hospital Universitario de Canarias, La Laguna, Tenerife, Spain; Complejo Hospitalario de Jaén, Jaén, Spain; Hospital Universitari Son Espases, Palma de Mallorca, Spain; GEICAM, Spanish Breast Cancer Group, Madr
| | - A Perelló
- Translational Genomics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Hospital Clínic de Barcelona, Barcelona, Spain; Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC)– H. Universitario Reina Sofía, Universidad de Córdoba, Córdoba, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Clínico San Carlos, Madrid, Spain; Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain; Hospital Universitario Miguel Servet, Zaragoza, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Hospital Universitario Ramón y Cajal, Madrid, Spain; Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain; Hospital del Mar, Barcelona, Spain; Fundación Jiménez Díaz, Madrid, Spain; Hospital Universitari Mutua de Terrassa, Terrassa, Barcelona, Spain; Hospital Universitario de Canarias, La Laguna, Tenerife, Spain; Complejo Hospitalario de Jaén, Jaén, Spain; Hospital Universitari Son Espases, Palma de Mallorca, Spain; GEICAM, Spanish Breast Cancer Group, Madr
| | - C Rodríguez-Martin
- Translational Genomics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Hospital Clínic de Barcelona, Barcelona, Spain; Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC)– H. Universitario Reina Sofía, Universidad de Córdoba, Córdoba, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Clínico San Carlos, Madrid, Spain; Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain; Hospital Universitario Miguel Servet, Zaragoza, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Hospital Universitario Ramón y Cajal, Madrid, Spain; Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain; Hospital del Mar, Barcelona, Spain; Fundación Jiménez Díaz, Madrid, Spain; Hospital Universitari Mutua de Terrassa, Terrassa, Barcelona, Spain; Hospital Universitario de Canarias, La Laguna, Tenerife, Spain; Complejo Hospitalario de Jaén, Jaén, Spain; Hospital Universitari Son Espases, Palma de Mallorca, Spain; GEICAM, Spanish Breast Cancer Group, Madr
| | - M Casas
- Translational Genomics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Hospital Clínic de Barcelona, Barcelona, Spain; Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC)– H. Universitario Reina Sofía, Universidad de Córdoba, Córdoba, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Clínico San Carlos, Madrid, Spain; Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain; Hospital Universitario Miguel Servet, Zaragoza, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Hospital Universitario Ramón y Cajal, Madrid, Spain; Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain; Hospital del Mar, Barcelona, Spain; Fundación Jiménez Díaz, Madrid, Spain; Hospital Universitari Mutua de Terrassa, Terrassa, Barcelona, Spain; Hospital Universitario de Canarias, La Laguna, Tenerife, Spain; Complejo Hospitalario de Jaén, Jaén, Spain; Hospital Universitari Son Espases, Palma de Mallorca, Spain; GEICAM, Spanish Breast Cancer Group, Madr
| | - E Carrasco
- Translational Genomics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Hospital Clínic de Barcelona, Barcelona, Spain; Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC)– H. Universitario Reina Sofía, Universidad de Córdoba, Córdoba, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Clínico San Carlos, Madrid, Spain; Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain; Hospital Universitario Miguel Servet, Zaragoza, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Hospital Universitario Ramón y Cajal, Madrid, Spain; Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain; Hospital del Mar, Barcelona, Spain; Fundación Jiménez Díaz, Madrid, Spain; Hospital Universitari Mutua de Terrassa, Terrassa, Barcelona, Spain; Hospital Universitario de Canarias, La Laguna, Tenerife, Spain; Complejo Hospitalario de Jaén, Jaén, Spain; Hospital Universitari Son Espases, Palma de Mallorca, Spain; GEICAM, Spanish Breast Cancer Group, Madr
| | - R Caballero
- Translational Genomics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Hospital Clínic de Barcelona, Barcelona, Spain; Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC)– H. Universitario Reina Sofía, Universidad de Córdoba, Córdoba, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Clínico San Carlos, Madrid, Spain; Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain; Hospital Universitario Miguel Servet, Zaragoza, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Hospital Universitario Ramón y Cajal, Madrid, Spain; Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain; Hospital del Mar, Barcelona, Spain; Fundación Jiménez Díaz, Madrid, Spain; Hospital Universitari Mutua de Terrassa, Terrassa, Barcelona, Spain; Hospital Universitario de Canarias, La Laguna, Tenerife, Spain; Complejo Hospitalario de Jaén, Jaén, Spain; Hospital Universitari Son Espases, Palma de Mallorca, Spain; GEICAM, Spanish Breast Cancer Group, Madr
| | - M Martín
- Translational Genomics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Hospital Clínic de Barcelona, Barcelona, Spain; Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC)– H. Universitario Reina Sofía, Universidad de Córdoba, Córdoba, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Clínico San Carlos, Madrid, Spain; Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain; Hospital Universitario Miguel Servet, Zaragoza, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Hospital Universitario Ramón y Cajal, Madrid, Spain; Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain; Hospital del Mar, Barcelona, Spain; Fundación Jiménez Díaz, Madrid, Spain; Hospital Universitari Mutua de Terrassa, Terrassa, Barcelona, Spain; Hospital Universitario de Canarias, La Laguna, Tenerife, Spain; Complejo Hospitalario de Jaén, Jaén, Spain; Hospital Universitari Son Espases, Palma de Mallorca, Spain; GEICAM, Spanish Breast Cancer Group, Madr
| |
Collapse
|
5
|
Ocaña A, Ruiz Borrego M, Gil-Martín M, Antolín S, Guerrero Á, Vidal Boixader L, Martín M, Trigo Pérez JM, Rojo F, Jerez Y, Atienza M, Pernas S, Hernando A, Carrasco E, Benito S, Caballero R, Pandiella A. Abstract OT3-01-02: A phase I-II trial of dasatinib in combination with trastuzumab (T) and paclitaxel in the first line treatment of HER2 positive metastatic breast cancer (MBC) patients: GEICAM/2010-04. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-ot3-01-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Resistance to targeted-therapies is a current problem in our clinical practice. In HER2 overexpressing tumors, resistance to trastuzumab-based therapies is widely observed. Expression of SRC has been pre-clinically linked to trastuzumab resistance and the addition of the multi-tyrosine kinase inhibitor dasatinib to trastuzumab increases its antitumor activity (Seoane S, et al. J Natl Cancer Inst. 2010). On previous studies, Dasatinib showed a good toxicity profile, with low grade 3-4 toxicity rates (E. Mayer, et al. J Clin Oncol 2009). We have designed a phase I-II trial combining dasatinib with standard trastuzumab/paclitaxel. (ClinicalTrials.gov Identifier: NCT01306942). In this abstract we report the description of the phase II part of the trial which is ongoing.
Trial Design: Eligible patients must be HER2+ (evaluated by central laboratory and assessed by immunohistochemistry and fluorescent in-situ hybridization) MBC and candidates for trastuzumab + chemotherapy as first line treatment. Taxanes and trastuzumab administered in the adjuvant setting are permitted if given >12 months before the inclusion. Patients with CNS involvement are eligible if treated and clinically stable without medication. Treatment consists of trastuzumab 2 mg/kg weekly (following a loading dose of 4 mg/kg in cycle 1), weekly paclitaxel (80 mg/m2, 3 weeks on-one week off) and dasatinib 100 mg once daily (based on the recommended phase II dose from the phase I part, Gil-Martin M, et al. European Breast Cancer Conference 2014, P-041) in a 28-days cycle. Patients are treated until radiologic or symptomatic progression or unacceptable toxicity.
The primary objective for this phase II is efficacy, measured by Objective Response Rate (ORR according to RECIST 1.1). Secondary objectives are: Safety (evaluated using NCI-CTCAE v 4.03), Clinical Benefit Rate, Time to Progression, Progression Free Survival and Response Duration. Pharmacodynamic biomarkers include pAKT, pS6, pSRC, pErk1/2 in tumor tissue samples, mononuclear cells in blood samples and in skin tissue. An additional exploratory objective is to evaluate the correlation between the early presence of lymphocytosis and efficacy. The study will be considered positive if ORR increases 25% from a 50% ORR observed in previous studies with paclitaxel + trastuzumab. We need to include 28 evaluable patients to demonstrate this hypothesis (with an alpha error of 0.05 and a statistical power of 80%), assuming a 10% drop-out rate. Twenty one patients have already been included. Recruitment is expected to finish by the end of 2015.
Citation Format: Ocaña A, Ruiz Borrego M, Gil-Martín M, Antolín S, Guerrero Á, Vidal Boixader L, Martín M, Trigo Pérez JM, Rojo F, Jerez Y, Atienza M, Pernas S, Hernando A, Carrasco E, Benito S, Caballero R, Pandiella A. A phase I-II trial of dasatinib in combination with trastuzumab (T) and paclitaxel in the first line treatment of HER2 positive metastatic breast cancer (MBC) patients: GEICAM/2010-04. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr OT3-01-02.
Collapse
Affiliation(s)
- A Ocaña
- Complejo Hospitalario Universitario de Albacete, Albacete, Spain; Hospital Universitario Virgen del Rocío, Sevilla, Spain; Instituto Catalán de Oncología de L'Hospitalet, L'Hospitalet de Llobregat, Barcelona, Spain; Complejo Hospitalario Universitario A Coruña, A Coruña, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Clinic i Provincial de Barcelona, Barcelona, Spain; Instituto de Investigación Sanitaria Gregorio Marañón, Universidad Complutense de Madrid, Madrid, Spain; Hospital Clínico Universitario Virgen de la Victoria, Málaga, Spain; Fundación Jiménez Díaz, Madrid, Spain; Hospital General Universitario Gregorio Marañón, Madrid, Spain; GEICAM Spanish Breast Cancer Group, Madrid, Spain; Centro de Investigación del Cáncer, CSIC-Universidad de Salamanca, Salamanca, Spain
| | - M Ruiz Borrego
- Complejo Hospitalario Universitario de Albacete, Albacete, Spain; Hospital Universitario Virgen del Rocío, Sevilla, Spain; Instituto Catalán de Oncología de L'Hospitalet, L'Hospitalet de Llobregat, Barcelona, Spain; Complejo Hospitalario Universitario A Coruña, A Coruña, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Clinic i Provincial de Barcelona, Barcelona, Spain; Instituto de Investigación Sanitaria Gregorio Marañón, Universidad Complutense de Madrid, Madrid, Spain; Hospital Clínico Universitario Virgen de la Victoria, Málaga, Spain; Fundación Jiménez Díaz, Madrid, Spain; Hospital General Universitario Gregorio Marañón, Madrid, Spain; GEICAM Spanish Breast Cancer Group, Madrid, Spain; Centro de Investigación del Cáncer, CSIC-Universidad de Salamanca, Salamanca, Spain
| | - M Gil-Martín
- Complejo Hospitalario Universitario de Albacete, Albacete, Spain; Hospital Universitario Virgen del Rocío, Sevilla, Spain; Instituto Catalán de Oncología de L'Hospitalet, L'Hospitalet de Llobregat, Barcelona, Spain; Complejo Hospitalario Universitario A Coruña, A Coruña, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Clinic i Provincial de Barcelona, Barcelona, Spain; Instituto de Investigación Sanitaria Gregorio Marañón, Universidad Complutense de Madrid, Madrid, Spain; Hospital Clínico Universitario Virgen de la Victoria, Málaga, Spain; Fundación Jiménez Díaz, Madrid, Spain; Hospital General Universitario Gregorio Marañón, Madrid, Spain; GEICAM Spanish Breast Cancer Group, Madrid, Spain; Centro de Investigación del Cáncer, CSIC-Universidad de Salamanca, Salamanca, Spain
| | - S Antolín
- Complejo Hospitalario Universitario de Albacete, Albacete, Spain; Hospital Universitario Virgen del Rocío, Sevilla, Spain; Instituto Catalán de Oncología de L'Hospitalet, L'Hospitalet de Llobregat, Barcelona, Spain; Complejo Hospitalario Universitario A Coruña, A Coruña, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Clinic i Provincial de Barcelona, Barcelona, Spain; Instituto de Investigación Sanitaria Gregorio Marañón, Universidad Complutense de Madrid, Madrid, Spain; Hospital Clínico Universitario Virgen de la Victoria, Málaga, Spain; Fundación Jiménez Díaz, Madrid, Spain; Hospital General Universitario Gregorio Marañón, Madrid, Spain; GEICAM Spanish Breast Cancer Group, Madrid, Spain; Centro de Investigación del Cáncer, CSIC-Universidad de Salamanca, Salamanca, Spain
| | - Á Guerrero
- Complejo Hospitalario Universitario de Albacete, Albacete, Spain; Hospital Universitario Virgen del Rocío, Sevilla, Spain; Instituto Catalán de Oncología de L'Hospitalet, L'Hospitalet de Llobregat, Barcelona, Spain; Complejo Hospitalario Universitario A Coruña, A Coruña, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Clinic i Provincial de Barcelona, Barcelona, Spain; Instituto de Investigación Sanitaria Gregorio Marañón, Universidad Complutense de Madrid, Madrid, Spain; Hospital Clínico Universitario Virgen de la Victoria, Málaga, Spain; Fundación Jiménez Díaz, Madrid, Spain; Hospital General Universitario Gregorio Marañón, Madrid, Spain; GEICAM Spanish Breast Cancer Group, Madrid, Spain; Centro de Investigación del Cáncer, CSIC-Universidad de Salamanca, Salamanca, Spain
| | - L Vidal Boixader
- Complejo Hospitalario Universitario de Albacete, Albacete, Spain; Hospital Universitario Virgen del Rocío, Sevilla, Spain; Instituto Catalán de Oncología de L'Hospitalet, L'Hospitalet de Llobregat, Barcelona, Spain; Complejo Hospitalario Universitario A Coruña, A Coruña, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Clinic i Provincial de Barcelona, Barcelona, Spain; Instituto de Investigación Sanitaria Gregorio Marañón, Universidad Complutense de Madrid, Madrid, Spain; Hospital Clínico Universitario Virgen de la Victoria, Málaga, Spain; Fundación Jiménez Díaz, Madrid, Spain; Hospital General Universitario Gregorio Marañón, Madrid, Spain; GEICAM Spanish Breast Cancer Group, Madrid, Spain; Centro de Investigación del Cáncer, CSIC-Universidad de Salamanca, Salamanca, Spain
| | - M Martín
- Complejo Hospitalario Universitario de Albacete, Albacete, Spain; Hospital Universitario Virgen del Rocío, Sevilla, Spain; Instituto Catalán de Oncología de L'Hospitalet, L'Hospitalet de Llobregat, Barcelona, Spain; Complejo Hospitalario Universitario A Coruña, A Coruña, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Clinic i Provincial de Barcelona, Barcelona, Spain; Instituto de Investigación Sanitaria Gregorio Marañón, Universidad Complutense de Madrid, Madrid, Spain; Hospital Clínico Universitario Virgen de la Victoria, Málaga, Spain; Fundación Jiménez Díaz, Madrid, Spain; Hospital General Universitario Gregorio Marañón, Madrid, Spain; GEICAM Spanish Breast Cancer Group, Madrid, Spain; Centro de Investigación del Cáncer, CSIC-Universidad de Salamanca, Salamanca, Spain
| | - JM Trigo Pérez
- Complejo Hospitalario Universitario de Albacete, Albacete, Spain; Hospital Universitario Virgen del Rocío, Sevilla, Spain; Instituto Catalán de Oncología de L'Hospitalet, L'Hospitalet de Llobregat, Barcelona, Spain; Complejo Hospitalario Universitario A Coruña, A Coruña, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Clinic i Provincial de Barcelona, Barcelona, Spain; Instituto de Investigación Sanitaria Gregorio Marañón, Universidad Complutense de Madrid, Madrid, Spain; Hospital Clínico Universitario Virgen de la Victoria, Málaga, Spain; Fundación Jiménez Díaz, Madrid, Spain; Hospital General Universitario Gregorio Marañón, Madrid, Spain; GEICAM Spanish Breast Cancer Group, Madrid, Spain; Centro de Investigación del Cáncer, CSIC-Universidad de Salamanca, Salamanca, Spain
| | - F Rojo
- Complejo Hospitalario Universitario de Albacete, Albacete, Spain; Hospital Universitario Virgen del Rocío, Sevilla, Spain; Instituto Catalán de Oncología de L'Hospitalet, L'Hospitalet de Llobregat, Barcelona, Spain; Complejo Hospitalario Universitario A Coruña, A Coruña, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Clinic i Provincial de Barcelona, Barcelona, Spain; Instituto de Investigación Sanitaria Gregorio Marañón, Universidad Complutense de Madrid, Madrid, Spain; Hospital Clínico Universitario Virgen de la Victoria, Málaga, Spain; Fundación Jiménez Díaz, Madrid, Spain; Hospital General Universitario Gregorio Marañón, Madrid, Spain; GEICAM Spanish Breast Cancer Group, Madrid, Spain; Centro de Investigación del Cáncer, CSIC-Universidad de Salamanca, Salamanca, Spain
| | - Y Jerez
- Complejo Hospitalario Universitario de Albacete, Albacete, Spain; Hospital Universitario Virgen del Rocío, Sevilla, Spain; Instituto Catalán de Oncología de L'Hospitalet, L'Hospitalet de Llobregat, Barcelona, Spain; Complejo Hospitalario Universitario A Coruña, A Coruña, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Clinic i Provincial de Barcelona, Barcelona, Spain; Instituto de Investigación Sanitaria Gregorio Marañón, Universidad Complutense de Madrid, Madrid, Spain; Hospital Clínico Universitario Virgen de la Victoria, Málaga, Spain; Fundación Jiménez Díaz, Madrid, Spain; Hospital General Universitario Gregorio Marañón, Madrid, Spain; GEICAM Spanish Breast Cancer Group, Madrid, Spain; Centro de Investigación del Cáncer, CSIC-Universidad de Salamanca, Salamanca, Spain
| | - M Atienza
- Complejo Hospitalario Universitario de Albacete, Albacete, Spain; Hospital Universitario Virgen del Rocío, Sevilla, Spain; Instituto Catalán de Oncología de L'Hospitalet, L'Hospitalet de Llobregat, Barcelona, Spain; Complejo Hospitalario Universitario A Coruña, A Coruña, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Clinic i Provincial de Barcelona, Barcelona, Spain; Instituto de Investigación Sanitaria Gregorio Marañón, Universidad Complutense de Madrid, Madrid, Spain; Hospital Clínico Universitario Virgen de la Victoria, Málaga, Spain; Fundación Jiménez Díaz, Madrid, Spain; Hospital General Universitario Gregorio Marañón, Madrid, Spain; GEICAM Spanish Breast Cancer Group, Madrid, Spain; Centro de Investigación del Cáncer, CSIC-Universidad de Salamanca, Salamanca, Spain
| | - S Pernas
- Complejo Hospitalario Universitario de Albacete, Albacete, Spain; Hospital Universitario Virgen del Rocío, Sevilla, Spain; Instituto Catalán de Oncología de L'Hospitalet, L'Hospitalet de Llobregat, Barcelona, Spain; Complejo Hospitalario Universitario A Coruña, A Coruña, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Clinic i Provincial de Barcelona, Barcelona, Spain; Instituto de Investigación Sanitaria Gregorio Marañón, Universidad Complutense de Madrid, Madrid, Spain; Hospital Clínico Universitario Virgen de la Victoria, Málaga, Spain; Fundación Jiménez Díaz, Madrid, Spain; Hospital General Universitario Gregorio Marañón, Madrid, Spain; GEICAM Spanish Breast Cancer Group, Madrid, Spain; Centro de Investigación del Cáncer, CSIC-Universidad de Salamanca, Salamanca, Spain
| | - A Hernando
- Complejo Hospitalario Universitario de Albacete, Albacete, Spain; Hospital Universitario Virgen del Rocío, Sevilla, Spain; Instituto Catalán de Oncología de L'Hospitalet, L'Hospitalet de Llobregat, Barcelona, Spain; Complejo Hospitalario Universitario A Coruña, A Coruña, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Clinic i Provincial de Barcelona, Barcelona, Spain; Instituto de Investigación Sanitaria Gregorio Marañón, Universidad Complutense de Madrid, Madrid, Spain; Hospital Clínico Universitario Virgen de la Victoria, Málaga, Spain; Fundación Jiménez Díaz, Madrid, Spain; Hospital General Universitario Gregorio Marañón, Madrid, Spain; GEICAM Spanish Breast Cancer Group, Madrid, Spain; Centro de Investigación del Cáncer, CSIC-Universidad de Salamanca, Salamanca, Spain
| | - E Carrasco
- Complejo Hospitalario Universitario de Albacete, Albacete, Spain; Hospital Universitario Virgen del Rocío, Sevilla, Spain; Instituto Catalán de Oncología de L'Hospitalet, L'Hospitalet de Llobregat, Barcelona, Spain; Complejo Hospitalario Universitario A Coruña, A Coruña, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Clinic i Provincial de Barcelona, Barcelona, Spain; Instituto de Investigación Sanitaria Gregorio Marañón, Universidad Complutense de Madrid, Madrid, Spain; Hospital Clínico Universitario Virgen de la Victoria, Málaga, Spain; Fundación Jiménez Díaz, Madrid, Spain; Hospital General Universitario Gregorio Marañón, Madrid, Spain; GEICAM Spanish Breast Cancer Group, Madrid, Spain; Centro de Investigación del Cáncer, CSIC-Universidad de Salamanca, Salamanca, Spain
| | - S Benito
- Complejo Hospitalario Universitario de Albacete, Albacete, Spain; Hospital Universitario Virgen del Rocío, Sevilla, Spain; Instituto Catalán de Oncología de L'Hospitalet, L'Hospitalet de Llobregat, Barcelona, Spain; Complejo Hospitalario Universitario A Coruña, A Coruña, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Clinic i Provincial de Barcelona, Barcelona, Spain; Instituto de Investigación Sanitaria Gregorio Marañón, Universidad Complutense de Madrid, Madrid, Spain; Hospital Clínico Universitario Virgen de la Victoria, Málaga, Spain; Fundación Jiménez Díaz, Madrid, Spain; Hospital General Universitario Gregorio Marañón, Madrid, Spain; GEICAM Spanish Breast Cancer Group, Madrid, Spain; Centro de Investigación del Cáncer, CSIC-Universidad de Salamanca, Salamanca, Spain
| | - R Caballero
- Complejo Hospitalario Universitario de Albacete, Albacete, Spain; Hospital Universitario Virgen del Rocío, Sevilla, Spain; Instituto Catalán de Oncología de L'Hospitalet, L'Hospitalet de Llobregat, Barcelona, Spain; Complejo Hospitalario Universitario A Coruña, A Coruña, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Clinic i Provincial de Barcelona, Barcelona, Spain; Instituto de Investigación Sanitaria Gregorio Marañón, Universidad Complutense de Madrid, Madrid, Spain; Hospital Clínico Universitario Virgen de la Victoria, Málaga, Spain; Fundación Jiménez Díaz, Madrid, Spain; Hospital General Universitario Gregorio Marañón, Madrid, Spain; GEICAM Spanish Breast Cancer Group, Madrid, Spain; Centro de Investigación del Cáncer, CSIC-Universidad de Salamanca, Salamanca, Spain
| | - A Pandiella
- Complejo Hospitalario Universitario de Albacete, Albacete, Spain; Hospital Universitario Virgen del Rocío, Sevilla, Spain; Instituto Catalán de Oncología de L'Hospitalet, L'Hospitalet de Llobregat, Barcelona, Spain; Complejo Hospitalario Universitario A Coruña, A Coruña, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Clinic i Provincial de Barcelona, Barcelona, Spain; Instituto de Investigación Sanitaria Gregorio Marañón, Universidad Complutense de Madrid, Madrid, Spain; Hospital Clínico Universitario Virgen de la Victoria, Málaga, Spain; Fundación Jiménez Díaz, Madrid, Spain; Hospital General Universitario Gregorio Marañón, Madrid, Spain; GEICAM Spanish Breast Cancer Group, Madrid, Spain; Centro de Investigación del Cáncer, CSIC-Universidad de Salamanca, Salamanca, Spain
| |
Collapse
|
6
|
Prat A, Martínez de Dueñas E, Galván P, Garcia S, Burgués O, Paré L, Antolín S, Martinello R, Blancas I, Adamo B, Guerrero Á, Muñoz M, Nuciforo P, Vidal M, Pérez RM, Chacón JI, Caballero R, Gascón P, Carrasco E, Rojo F, Perou CM, Cortés J, Adamo V, Albanell J, Lluch A. Abstract P6-05-02: Intrinsic subtype and gene expression changes between primary and metastatic breast cancer. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p6-05-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: A better understanding of the biological changes occurring during metastatic progression of breast cancer is needed to identify new biomarkers, targets and novel treatment strategies. Here, we compared the intrinsic subtype and the expression of a gene panel across a large dataset of paired primary and metastatic tissues.
Methods: Expression profiling of 105 breast cancer-related genes was performed on 254 (127 pairs) formalin-fixed paraffin-embedded tumor tissues using the nCounter platform. Tumor samples were obtained from 3 independent sources (ConvertHER trial [BCRT 2014] and two in-house datasets). Tumors were classified into each intrinsic subtype using the research-based PAM50 classifier (Parker et al. J Clin Oncol 2009). Chi-square tests were performed to determine the differences in the distribution of variables. Paired two-class Significance of Microarrays (SAM) was performed to determine the genes differentially expressed between paired primary and metastatic tissues. In vitro stable transfection of FGFR4-GFP was performed on Luminal B MCF7 cell line. RNA was purified on control vs. transfected cell lines. 7-AAD cell viability was performed following estrogen deprivation for 6 days.
Results: Subtype distribution in primary vs. metastatic disease was 39.0% vs. 26.8% for Luminal A (p=0.012), 26.0% vs. 35.0% for Luminal B (p=0.322), 11.4% vs. 20.3% for HER2-enriched (p=0.115) and 10.6% vs. 13.0% for Basal-like tumors (p=0.843). The rate of subtype conversion was 7.7% in Basal-like, 23.1% in HER2-enriched, 30.0% in Luminal B and 54.3% in Luminal A disease. The majority of subtype conversions in Luminal A disease were to Luminal B (72.0%) and HER2-enriched (24.0%). Overall, 13.2% of primary Luminal A/B tumors progressed to a HER2-E subtype despite 70% of them being clinically HER2-negative. In a paired analysis using all samples, 10- and 12- genes were found up- and down- regulated in metastatic tissues (False Discovery Rate [FDR] <5%). The up-regulated gene list in metastatic disease was composed of FGFR4 (top gene) and proliferation genes (CDC6, CCNB1, CEP55). The down-regulated gene list in metastatic disease was enriched for luminal-related genes (ESR1, PGR, NAT1 and MAPT). A similar paired analysis within Luminal A, Luminal B, HER2-enriched and Basal-like disease revealed 22, 8, 7 and 0 differentially expressed genes (FDR<5%), respectively. Finally, MCF7 cell line transfected with FGFR4 showed a relative increase in the HER2-enriched profile compared with transfected control. In vitro, MCF7-FGFR4 cells showed estrogen independent growth compared to transfected controls.
Conclusions: Metastatic tissues are relatively more proliferative and less luminal compared to primary tumors. This is especially relevant in primary Luminal A disease. In contrast, metastatic tissues from Basal-like primary disease remain largely unchanged. In luminal disease, a significant increase in the HER2-enriched profile is observed in metastatic disease despite most tumors being clinically HER2-negative. A potential driver of the HER2-enriched profile and estrogen independence in clinically HER2-negative metastatic tissues might be FGFR4.
Citation Format: Prat A, Martínez de Dueñas E, Galván P, Garcia S, Burgués O, Paré L, Antolín S, Martinello R, Blancas I, Adamo B, Guerrero Á, Muñoz M, Nuciforo P, Vidal M, Pérez RM, Chacón JI, Caballero R, Gascón P, Carrasco E, Rojo F, Perou CM, Cortés J, Adamo V, Albanell J, Lluch A. Intrinsic subtype and gene expression changes between primary and metastatic breast cancer. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P6-05-02.
Collapse
Affiliation(s)
- A Prat
- Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Hospital Clínic -- IDIBAPS, Barcelona, Spain; Hospital Provincial de Castellón, Castellón, Spain; Hospital Clínico Universitario de Valencia, Valencia, Spain; Complejo Hospitalario Universitario A Coruña, A Coruña, Spain; Hospital Clínico San Cecilio de Granada, Granada, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Universitario Quirón de Madrid, Madrid, Spain; Hospital Virgen de la Salud, Toledo, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Fundación Jiménez Díaz, Madrid, Spain; University of North Carolina, Chapel Hill, NC; University of Messina, Messina, Italy; Hospital del Mar, Barcelona, Spain
| | - E Martínez de Dueñas
- Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Hospital Clínic -- IDIBAPS, Barcelona, Spain; Hospital Provincial de Castellón, Castellón, Spain; Hospital Clínico Universitario de Valencia, Valencia, Spain; Complejo Hospitalario Universitario A Coruña, A Coruña, Spain; Hospital Clínico San Cecilio de Granada, Granada, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Universitario Quirón de Madrid, Madrid, Spain; Hospital Virgen de la Salud, Toledo, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Fundación Jiménez Díaz, Madrid, Spain; University of North Carolina, Chapel Hill, NC; University of Messina, Messina, Italy; Hospital del Mar, Barcelona, Spain
| | - P Galván
- Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Hospital Clínic -- IDIBAPS, Barcelona, Spain; Hospital Provincial de Castellón, Castellón, Spain; Hospital Clínico Universitario de Valencia, Valencia, Spain; Complejo Hospitalario Universitario A Coruña, A Coruña, Spain; Hospital Clínico San Cecilio de Granada, Granada, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Universitario Quirón de Madrid, Madrid, Spain; Hospital Virgen de la Salud, Toledo, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Fundación Jiménez Díaz, Madrid, Spain; University of North Carolina, Chapel Hill, NC; University of Messina, Messina, Italy; Hospital del Mar, Barcelona, Spain
| | - S Garcia
- Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Hospital Clínic -- IDIBAPS, Barcelona, Spain; Hospital Provincial de Castellón, Castellón, Spain; Hospital Clínico Universitario de Valencia, Valencia, Spain; Complejo Hospitalario Universitario A Coruña, A Coruña, Spain; Hospital Clínico San Cecilio de Granada, Granada, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Universitario Quirón de Madrid, Madrid, Spain; Hospital Virgen de la Salud, Toledo, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Fundación Jiménez Díaz, Madrid, Spain; University of North Carolina, Chapel Hill, NC; University of Messina, Messina, Italy; Hospital del Mar, Barcelona, Spain
| | - O Burgués
- Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Hospital Clínic -- IDIBAPS, Barcelona, Spain; Hospital Provincial de Castellón, Castellón, Spain; Hospital Clínico Universitario de Valencia, Valencia, Spain; Complejo Hospitalario Universitario A Coruña, A Coruña, Spain; Hospital Clínico San Cecilio de Granada, Granada, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Universitario Quirón de Madrid, Madrid, Spain; Hospital Virgen de la Salud, Toledo, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Fundación Jiménez Díaz, Madrid, Spain; University of North Carolina, Chapel Hill, NC; University of Messina, Messina, Italy; Hospital del Mar, Barcelona, Spain
| | - L Paré
- Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Hospital Clínic -- IDIBAPS, Barcelona, Spain; Hospital Provincial de Castellón, Castellón, Spain; Hospital Clínico Universitario de Valencia, Valencia, Spain; Complejo Hospitalario Universitario A Coruña, A Coruña, Spain; Hospital Clínico San Cecilio de Granada, Granada, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Universitario Quirón de Madrid, Madrid, Spain; Hospital Virgen de la Salud, Toledo, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Fundación Jiménez Díaz, Madrid, Spain; University of North Carolina, Chapel Hill, NC; University of Messina, Messina, Italy; Hospital del Mar, Barcelona, Spain
| | - S Antolín
- Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Hospital Clínic -- IDIBAPS, Barcelona, Spain; Hospital Provincial de Castellón, Castellón, Spain; Hospital Clínico Universitario de Valencia, Valencia, Spain; Complejo Hospitalario Universitario A Coruña, A Coruña, Spain; Hospital Clínico San Cecilio de Granada, Granada, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Universitario Quirón de Madrid, Madrid, Spain; Hospital Virgen de la Salud, Toledo, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Fundación Jiménez Díaz, Madrid, Spain; University of North Carolina, Chapel Hill, NC; University of Messina, Messina, Italy; Hospital del Mar, Barcelona, Spain
| | - R Martinello
- Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Hospital Clínic -- IDIBAPS, Barcelona, Spain; Hospital Provincial de Castellón, Castellón, Spain; Hospital Clínico Universitario de Valencia, Valencia, Spain; Complejo Hospitalario Universitario A Coruña, A Coruña, Spain; Hospital Clínico San Cecilio de Granada, Granada, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Universitario Quirón de Madrid, Madrid, Spain; Hospital Virgen de la Salud, Toledo, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Fundación Jiménez Díaz, Madrid, Spain; University of North Carolina, Chapel Hill, NC; University of Messina, Messina, Italy; Hospital del Mar, Barcelona, Spain
| | - I Blancas
- Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Hospital Clínic -- IDIBAPS, Barcelona, Spain; Hospital Provincial de Castellón, Castellón, Spain; Hospital Clínico Universitario de Valencia, Valencia, Spain; Complejo Hospitalario Universitario A Coruña, A Coruña, Spain; Hospital Clínico San Cecilio de Granada, Granada, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Universitario Quirón de Madrid, Madrid, Spain; Hospital Virgen de la Salud, Toledo, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Fundación Jiménez Díaz, Madrid, Spain; University of North Carolina, Chapel Hill, NC; University of Messina, Messina, Italy; Hospital del Mar, Barcelona, Spain
| | - B Adamo
- Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Hospital Clínic -- IDIBAPS, Barcelona, Spain; Hospital Provincial de Castellón, Castellón, Spain; Hospital Clínico Universitario de Valencia, Valencia, Spain; Complejo Hospitalario Universitario A Coruña, A Coruña, Spain; Hospital Clínico San Cecilio de Granada, Granada, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Universitario Quirón de Madrid, Madrid, Spain; Hospital Virgen de la Salud, Toledo, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Fundación Jiménez Díaz, Madrid, Spain; University of North Carolina, Chapel Hill, NC; University of Messina, Messina, Italy; Hospital del Mar, Barcelona, Spain
| | - Á Guerrero
- Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Hospital Clínic -- IDIBAPS, Barcelona, Spain; Hospital Provincial de Castellón, Castellón, Spain; Hospital Clínico Universitario de Valencia, Valencia, Spain; Complejo Hospitalario Universitario A Coruña, A Coruña, Spain; Hospital Clínico San Cecilio de Granada, Granada, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Universitario Quirón de Madrid, Madrid, Spain; Hospital Virgen de la Salud, Toledo, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Fundación Jiménez Díaz, Madrid, Spain; University of North Carolina, Chapel Hill, NC; University of Messina, Messina, Italy; Hospital del Mar, Barcelona, Spain
| | - M Muñoz
- Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Hospital Clínic -- IDIBAPS, Barcelona, Spain; Hospital Provincial de Castellón, Castellón, Spain; Hospital Clínico Universitario de Valencia, Valencia, Spain; Complejo Hospitalario Universitario A Coruña, A Coruña, Spain; Hospital Clínico San Cecilio de Granada, Granada, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Universitario Quirón de Madrid, Madrid, Spain; Hospital Virgen de la Salud, Toledo, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Fundación Jiménez Díaz, Madrid, Spain; University of North Carolina, Chapel Hill, NC; University of Messina, Messina, Italy; Hospital del Mar, Barcelona, Spain
| | - P Nuciforo
- Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Hospital Clínic -- IDIBAPS, Barcelona, Spain; Hospital Provincial de Castellón, Castellón, Spain; Hospital Clínico Universitario de Valencia, Valencia, Spain; Complejo Hospitalario Universitario A Coruña, A Coruña, Spain; Hospital Clínico San Cecilio de Granada, Granada, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Universitario Quirón de Madrid, Madrid, Spain; Hospital Virgen de la Salud, Toledo, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Fundación Jiménez Díaz, Madrid, Spain; University of North Carolina, Chapel Hill, NC; University of Messina, Messina, Italy; Hospital del Mar, Barcelona, Spain
| | - M Vidal
- Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Hospital Clínic -- IDIBAPS, Barcelona, Spain; Hospital Provincial de Castellón, Castellón, Spain; Hospital Clínico Universitario de Valencia, Valencia, Spain; Complejo Hospitalario Universitario A Coruña, A Coruña, Spain; Hospital Clínico San Cecilio de Granada, Granada, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Universitario Quirón de Madrid, Madrid, Spain; Hospital Virgen de la Salud, Toledo, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Fundación Jiménez Díaz, Madrid, Spain; University of North Carolina, Chapel Hill, NC; University of Messina, Messina, Italy; Hospital del Mar, Barcelona, Spain
| | - RM Pérez
- Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Hospital Clínic -- IDIBAPS, Barcelona, Spain; Hospital Provincial de Castellón, Castellón, Spain; Hospital Clínico Universitario de Valencia, Valencia, Spain; Complejo Hospitalario Universitario A Coruña, A Coruña, Spain; Hospital Clínico San Cecilio de Granada, Granada, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Universitario Quirón de Madrid, Madrid, Spain; Hospital Virgen de la Salud, Toledo, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Fundación Jiménez Díaz, Madrid, Spain; University of North Carolina, Chapel Hill, NC; University of Messina, Messina, Italy; Hospital del Mar, Barcelona, Spain
| | - JI Chacón
- Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Hospital Clínic -- IDIBAPS, Barcelona, Spain; Hospital Provincial de Castellón, Castellón, Spain; Hospital Clínico Universitario de Valencia, Valencia, Spain; Complejo Hospitalario Universitario A Coruña, A Coruña, Spain; Hospital Clínico San Cecilio de Granada, Granada, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Universitario Quirón de Madrid, Madrid, Spain; Hospital Virgen de la Salud, Toledo, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Fundación Jiménez Díaz, Madrid, Spain; University of North Carolina, Chapel Hill, NC; University of Messina, Messina, Italy; Hospital del Mar, Barcelona, Spain
| | - R Caballero
- Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Hospital Clínic -- IDIBAPS, Barcelona, Spain; Hospital Provincial de Castellón, Castellón, Spain; Hospital Clínico Universitario de Valencia, Valencia, Spain; Complejo Hospitalario Universitario A Coruña, A Coruña, Spain; Hospital Clínico San Cecilio de Granada, Granada, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Universitario Quirón de Madrid, Madrid, Spain; Hospital Virgen de la Salud, Toledo, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Fundación Jiménez Díaz, Madrid, Spain; University of North Carolina, Chapel Hill, NC; University of Messina, Messina, Italy; Hospital del Mar, Barcelona, Spain
| | - P Gascón
- Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Hospital Clínic -- IDIBAPS, Barcelona, Spain; Hospital Provincial de Castellón, Castellón, Spain; Hospital Clínico Universitario de Valencia, Valencia, Spain; Complejo Hospitalario Universitario A Coruña, A Coruña, Spain; Hospital Clínico San Cecilio de Granada, Granada, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Universitario Quirón de Madrid, Madrid, Spain; Hospital Virgen de la Salud, Toledo, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Fundación Jiménez Díaz, Madrid, Spain; University of North Carolina, Chapel Hill, NC; University of Messina, Messina, Italy; Hospital del Mar, Barcelona, Spain
| | - E Carrasco
- Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Hospital Clínic -- IDIBAPS, Barcelona, Spain; Hospital Provincial de Castellón, Castellón, Spain; Hospital Clínico Universitario de Valencia, Valencia, Spain; Complejo Hospitalario Universitario A Coruña, A Coruña, Spain; Hospital Clínico San Cecilio de Granada, Granada, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Universitario Quirón de Madrid, Madrid, Spain; Hospital Virgen de la Salud, Toledo, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Fundación Jiménez Díaz, Madrid, Spain; University of North Carolina, Chapel Hill, NC; University of Messina, Messina, Italy; Hospital del Mar, Barcelona, Spain
| | - F Rojo
- Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Hospital Clínic -- IDIBAPS, Barcelona, Spain; Hospital Provincial de Castellón, Castellón, Spain; Hospital Clínico Universitario de Valencia, Valencia, Spain; Complejo Hospitalario Universitario A Coruña, A Coruña, Spain; Hospital Clínico San Cecilio de Granada, Granada, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Universitario Quirón de Madrid, Madrid, Spain; Hospital Virgen de la Salud, Toledo, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Fundación Jiménez Díaz, Madrid, Spain; University of North Carolina, Chapel Hill, NC; University of Messina, Messina, Italy; Hospital del Mar, Barcelona, Spain
| | - CM Perou
- Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Hospital Clínic -- IDIBAPS, Barcelona, Spain; Hospital Provincial de Castellón, Castellón, Spain; Hospital Clínico Universitario de Valencia, Valencia, Spain; Complejo Hospitalario Universitario A Coruña, A Coruña, Spain; Hospital Clínico San Cecilio de Granada, Granada, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Universitario Quirón de Madrid, Madrid, Spain; Hospital Virgen de la Salud, Toledo, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Fundación Jiménez Díaz, Madrid, Spain; University of North Carolina, Chapel Hill, NC; University of Messina, Messina, Italy; Hospital del Mar, Barcelona, Spain
| | - J Cortés
- Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Hospital Clínic -- IDIBAPS, Barcelona, Spain; Hospital Provincial de Castellón, Castellón, Spain; Hospital Clínico Universitario de Valencia, Valencia, Spain; Complejo Hospitalario Universitario A Coruña, A Coruña, Spain; Hospital Clínico San Cecilio de Granada, Granada, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Universitario Quirón de Madrid, Madrid, Spain; Hospital Virgen de la Salud, Toledo, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Fundación Jiménez Díaz, Madrid, Spain; University of North Carolina, Chapel Hill, NC; University of Messina, Messina, Italy; Hospital del Mar, Barcelona, Spain
| | - V Adamo
- Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Hospital Clínic -- IDIBAPS, Barcelona, Spain; Hospital Provincial de Castellón, Castellón, Spain; Hospital Clínico Universitario de Valencia, Valencia, Spain; Complejo Hospitalario Universitario A Coruña, A Coruña, Spain; Hospital Clínico San Cecilio de Granada, Granada, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Universitario Quirón de Madrid, Madrid, Spain; Hospital Virgen de la Salud, Toledo, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Fundación Jiménez Díaz, Madrid, Spain; University of North Carolina, Chapel Hill, NC; University of Messina, Messina, Italy; Hospital del Mar, Barcelona, Spain
| | - J Albanell
- Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Hospital Clínic -- IDIBAPS, Barcelona, Spain; Hospital Provincial de Castellón, Castellón, Spain; Hospital Clínico Universitario de Valencia, Valencia, Spain; Complejo Hospitalario Universitario A Coruña, A Coruña, Spain; Hospital Clínico San Cecilio de Granada, Granada, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Universitario Quirón de Madrid, Madrid, Spain; Hospital Virgen de la Salud, Toledo, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Fundación Jiménez Díaz, Madrid, Spain; University of North Carolina, Chapel Hill, NC; University of Messina, Messina, Italy; Hospital del Mar, Barcelona, Spain
| | - A Lluch
- Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Hospital Clínic -- IDIBAPS, Barcelona, Spain; Hospital Provincial de Castellón, Castellón, Spain; Hospital Clínico Universitario de Valencia, Valencia, Spain; Complejo Hospitalario Universitario A Coruña, A Coruña, Spain; Hospital Clínico San Cecilio de Granada, Granada, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Universitario Quirón de Madrid, Madrid, Spain; Hospital Virgen de la Salud, Toledo, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Fundación Jiménez Díaz, Madrid, Spain; University of North Carolina, Chapel Hill, NC; University of Messina, Messina, Italy; Hospital del Mar, Barcelona, Spain
| |
Collapse
|